MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Legend Biotech Corp ADR

Closed

SectorHealthcare

34.21 -0.35

Overview

Share price change

24h

Current

Min

33.5

Max

34.41

Key metrics

By Trading Economics

Income

161M

41M

Sales

26M

187M

EPS

0.14

Profit margin

21.719

Employees

2,600

EBITDA

162M

52M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+141.5% upside

Dividends

By Dow Jones

Next Earnings

12 maj 2025

Market Stats

By TradingEconomics

Market Cap

-549M

5.9B

Previous open

34.56

Previous close

34.21

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Legend Biotech Corp ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 maj 2024, 11:36 UTC

Earnings

Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales

11 mar 2025, 11:09 UTC

Earnings

Legend Biotech 4Q Research and Development Expenses $104.4M >LEGN

11 mar 2025, 11:08 UTC

Earnings

Legend Biotech 4Q EPS 7c >LEGN

11 mar 2025, 11:00 UTC

Earnings

Legend Biotech 4Q Rev $186.5M >LEGN

12 lis 2024, 12:06 UTC

Earnings

Legend Biotech 3Q Loss/Shr 34c >LEGN

12 lis 2024, 12:05 UTC

Earnings

Legend Biotech 3Q Net Trade Sales ABout $286M >LEGN

12 lis 2024, 12:00 UTC

Earnings

Legend Biotech 3Q Rev $160.2M >LEGN

9 sie 2024, 11:02 UTC

Earnings

Legend Biotech 2Q License Rev Was $90.8M >LEGN

9 sie 2024, 11:01 UTC

Earnings

Legend Biotech 2Q Collaboration Rev $93.3M >LEGN

9 sie 2024, 11:01 UTC

Earnings

Legend Biotech 2Q Loss/Shr 5c >LEGN

9 sie 2024, 11:00 UTC

Earnings

Legend Biotech 2Q Rev $186.5M >LEGN

26 lip 2024, 11:01 UTC

Earnings

Legend Biotech Expects 2H Adjusted Net Loss $94.7M

13 maj 2024, 11:02 UTC

Earnings

Legend Biotech 1Q Loss/Shr 16c >LEGN

13 maj 2024, 11:02 UTC

Earnings

Legend Biotech 1Q Research and Development Expenses $101.0M >LEGN

Peer Comparison

Price change

Legend Biotech Corp ADR Forecast

Price Target

By TipRanks

141.5% upside

12 Months Forecast

Average 83.27 USD  141.5%

High 95 USD

Low 62 USD

Based on 14 Wall Street analysts offering 12 month price targets forLegend Biotech Corp ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

12

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

32.08 / 34.48Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.